GoldenGolden
Advanced Search

AgomAb (Company)

Agonistic monoclonal antibody molecules

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

March 10, 2021
AgomAb raises a $74,000,000 series B round.
April 2019
AgomAb raises a $23,600,000 series A round from Advent France Biotechnology, BIVF, Boehringer Ingelheim Venture Fund, Omnes Group, Pontifax Venture Capital and V-Bio Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.